Eyestem Research Secures $10M in Series B Funding to Democratize Access to Affordable Cell Therapy Solutions

Eyestem Research is proud to announce a major milestone in our journey to transform the cell and gene therapy landscape with the successful raise of $10,000,000 in new funding. This pivotal investment will fuel our mission to democratize access to life-changing cell therapies, which are currently priced at over $250,000 per injection—a cost that simply isn’t sustainable for the vast majority of patients around the world. With this fresh capital infusion, we are set to accelerate the development and clinical uptake of innovative therapies that offer hope and healing to a broader section of humanity. At the heart of our innovative portfolio is Eyecyte-RPE, our flagship project designed to treat incurable macular degeneration. With excellent efficacy results demonstrated thus far, Eyecyte-RPE is moving toward First-in-Man (FIM) trials, expected to begin in 2021. The upcoming trials mark a critical phase, not only validating the therapeutic potential of our approach but also setting new benchmarks in quality and affordability within the global cell therapy ecosystem. Our strategic vision is to disrupt the current market, leveraging advanced technologies and rigorous clinical data to overturn pricing paradigms and open the door to treatments that were once beyond reach for many patients. This funding round is a testament to our investors’ belief in our mission and our ability to redefine the industry landscape. By bridging the gap between cutting-edge research and scalable, equitable care, Eyestem Research is poised to make a lasting, positive impact on the future of cell therapy worldwide.